Literature DB >> 24797961

Barriers to the effective treatment of sepsis: antimicrobial agents, sepsis definitions, and host-directed therapies.

Ngan H Lyle1, Olga M Pena, John H Boyd, Robert E W Hancock.   

Abstract

Sepsis is a complex clinical syndrome involving both infection and a deleterious host immune response. Antimicrobial agents are key elements of sepsis treatment, yet despite great strides in antimicrobial development in the last decades, sepsis continues to be associated with unacceptably high mortality (~30%). This is the result, on one hand, of the rise of antimicrobial resistant organisms and, on the other hand, of the dearth of effective host-directed immune therapies. A major obstacle to the development of good host-directed therapies is the lack of understanding of the host immune response. The problem is exacerbated by poor nonspecific clinical definitions of disease. Poor definitions have had a profound impact on sepsis research, from epidemiologic studies to the failed clinical trials of host-directed therapies. Therefore, better definitions must be developed to enable advancement in the field.
© 2014 New York Academy of Sciences.

Entities:  

Keywords:  antimicrobial resistance; host-directed therapies; immunology; sepsis; sepsis definitions

Mesh:

Substances:

Year:  2014        PMID: 24797961     DOI: 10.1111/nyas.12444

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  21 in total

Review 1.  Antibiofilm Peptides: Potential as Broad-Spectrum Agents.

Authors:  Daniel Pletzer; Robert E W Hancock
Journal:  J Bacteriol       Date:  2016-09-09       Impact factor: 3.490

2.  Antibacterial Fusion Protein BPI21/LL-37 Modification Enhances the Therapeutic Efficacy of hUC-MSCs in Sepsis.

Authors:  Zhan Li; Yuqing Song; Peisong Yuan; Wei Guo; Xueting Hu; Wei Xing; Luoquan Ao; Yan Tan; Xiaofeng Wu; Xiang Ao; Xiao He; Dongpo Jiang; Huaping Liang; Xiang Xu
Journal:  Mol Ther       Date:  2020-05-15       Impact factor: 11.454

3.  Sepsis Treatment Options Are Often Lacking.

Authors:  Kunj Gohil
Journal:  P T       Date:  2015-07

4.  Effects of meglumine cyclic adenylate pretreatment on systemic inflammatory response syndrome induced by lipopolysaccharide in rats.

Authors:  Wei Liu; Jing-Li Chen; Henry Liu; Hong Yan
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2017-06-06

5.  Wnt5a/FZD5/CaMKII signaling pathway mediates the effect of BML-111 on inflammatory reactions in sepsis.

Authors:  Muhu Chen; Wu Zhong; Yingchun Hu; Jitao Liu; Xianfu Cai
Journal:  Int J Clin Exp Med       Date:  2015-10-15

6.  Warburg revisited: lessons for innate immunity and sepsis.

Authors:  Anup Srivastava; Praveen Mannam
Journal:  Front Physiol       Date:  2015-03-09       Impact factor: 4.566

Review 7.  Management of severe sepsis: advances, challenges, and current status.

Authors:  Ignacio Martin-Loeches; Mitchell M Levy; Antonio Artigas
Journal:  Drug Des Devel Ther       Date:  2015-04-09       Impact factor: 4.162

8.  An Endotoxin Tolerance Signature Predicts Sepsis and Organ Dysfunction at Initial Clinical Presentation.

Authors:  Olga M Pena; David G Hancock; Ngan H Lyle; Adam Linder; James A Russell; Jianguo Xia; Christopher D Fjell; John H Boyd; Robert E W Hancock
Journal:  EBioMedicine       Date:  2014-11-01       Impact factor: 8.143

9.  Identification of key genes in Gram‑positive and Gram‑negative sepsis using stochastic perturbation.

Authors:  Zhenliang Li; Ying Zhang; Yaling Liu; Yanchun Liu; Youyi Li
Journal:  Mol Med Rep       Date:  2017-07-15       Impact factor: 2.952

10.  Innate Immune Molecule Surfactant Protein D Attenuates Sepsis-induced Acute Pancreatic Injury through Modulating Apoptosis and NF-κB-mediated Inflammation.

Authors:  Zhiyong Liu; Qiao Shi; Jiao Liu; Osama Abdel-Razek; Yongan Xu; Robert N Cooney; Guirong Wang
Journal:  Sci Rep       Date:  2015-12-04       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.